Novo Nordisk initiates phase I pharmacokinetic study of NNC0148-0287sema in type 2 diabetes Jan. 28, 2019
VCN-01 shows promising activity in preclinical models and in phase I study of retinoblastoma Jan. 28, 2019
Immunosuppressive peptide R9-SOCS1-KIR prevents ocular damage in models of autoimmune uveitis Jan. 28, 2019
Collateral undamage: novel arterial growth mechanism underlies neonatal heart regeneration Jan. 28, 2019
Intrabone gene therapy with autologous HSCs for transfusion-dependent beta-thalassemia: phase I/II Jan. 28, 2019
RSS